You are here
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
Development of a Caregiver Application and AI-Enabled Intelligent Assistant to Support Families and Formal Care Providers in Caring for Persons with Alzheimer's Disease and Related DementiasSBC: Whiplash Technology, Inc. Topic: NIA
PROJECT ABSTRACT Family caregivers face daunting challenges in caring for persons with Alzheimer’s disease. Currently, there is no widely available mechanism to provide real-time, context sensitive support to informal AD caregivers that can address the specific care needs of each AD patient. To address this critical gap, we developed CareVirtue, an innovative web/mobile application for family ca ...STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
SBC: EyeMedix, Inc. Topic: N
DESCRIPTION provided by applicant Retinal diseases including age related macular degeneration AMD diabetic retinopathy DR diabetic macular edema DME and retina vein occlusion RVO are the leading causes of vision loss and blindness in people over years old According to the NEI in nearly million people in the U S suffered from some form of these diseases whose prevalen ...STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
SBC: TYMORA ANALYTICAL OPERATIONS LLC Topic: 102
PROJECT SUMMARY Reverse phase protein arrayRPPAhas emerged as a promising antibody based highly quantitative proteomic technology suitable for profiling proteins in hundreds to thousands of patient samplesThe throughputsensitivityand cost effectiveness of RPPAtogether with its ability to deal with minuscule sample amountshave propelled applications of the technology in basicpreclinical and clinica ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: TYMORA ANALYTICAL OPERATIONS LLC Topic: 400
PROJECT SUMMARY Thiopurines such as mercaptopurine are S-substituted antimetabolites used as functional analogs to natural nucleobase precursors. They are highly effective against hematologic malignancies (leukemia and lymphoma) and autoimmune diseases (inflammatory bowel diseases [IBD]), with an estimated patient population andgt;350,000 in the US. However, the cytotoxicity of thiopurines depends ...STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
SBC: TYMORA ANALYTICAL OPERATIONS LLC Topic: NIA
PROJECT SUMMARY The rising number of Americans currently living with Alzheimer’s disease (AD) demands pressing therapeutic and diagnostic solutions. The consensus is that early detection is critical to delay and better manage the disease. The recent discovery of extracellular vesicles (EVs) and their potentially important cellular functions in neuronal-glial communication, synaptic plasticity, o ...STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
SBC: Vivoscript, Inc. Topic: 200
DESCRIPTION provided by applicant The groundbreaking discovery of induced pluripotent stem cells iPSCs has opened a new page for developing personalized cell based therapies against various devastating human diseases without ethical concerns of using human embryonic stem cells However the future clinical applications of iPSCs remain in doubt due to potential risks of undesired genomic alter ...STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health
SBC: FasCure Therapeutics LLC Topic: 102
DESCRIPTION provided by applicant Therapeutics is focused on the development of adjuvant systems with desired immune activities for targeted indications The Companyandapos s immune stimulatory adjuvant platform builds on combinatorial use of immune agonists with distinct immune targets and mechanisms of action for the generation of therapeutic immune responses Critical to this platform techno ...STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
SBC: NEONC TECHNOLOGIES INC Topic: 102
Despite important advances in surgical techniques, imagistic modalities and computer-assisted stereotactic delivery of radiation therapy, the prognosis for patients with glioblastoma (GB) remains grim and has not significantly changed in decades. The Stupp protocol—i.e., concurrent temozolomide (TMZ) plus conformal external beam radiotherapy (EBRT) followed by adjuvant TMZ—remains the cornerst ...STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
SBC: KS & ASSOCIATES LLC Topic: NIEHS
PROJECT SUMMARY Chemical risk assessment is widely applied in industries and regulatory agencies as an important tool to evaluate chemical toxicity in support of chemical registration, safety evaluation, and exposure limitation development. One of the most notable improvements in dose-response assessment - a required quantitative step in risk assessment - is the development of benchmark dose (BMD) ...STTR Phase II 2020 Department of Health and Human ServicesNational Institutes of Health
SBC: SEACOAST SCIENCE, INC. Topic: NIEHS
Perfluoroalkyl substances (PFAS) such as perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate) are toxic and persistent compounds resulting from the production and use of fluoropolymers such as Gortex® and Teflon ®. The structure of PFAS preclude environmental degradation and can lead to bioaccumulation in animals and humans. Reported adverse effects of these compounds in humans include: ...STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health